RPbio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
RPbio is listed on KOSDAQ and classified under Health Care, Pharmaceuticals. Its market value is US$35.3M. In FY2025 it reported revenue of US$102.8M and operating profit of US$3.8M.
A written company profile is not available yet; the facts above come from exchange and DART data.
RPbio in five facts
Where is RPbio listed and in which sector?
RPbio (Korean name: 알피바이오) trades under KRX code 314140 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is RPbio?
Its market capitalisation was US$35.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were RPbio's latest annual revenue and operating profit?
For fiscal year 2025, RPbio reported revenue of US$102.8M, operating profit of US$3.8M and net income of US$3.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 9.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
RPbio declared a cash dividend of US$0.03 per share, equal to about 0.7% of the recent share price.
Dividend · Mar 16 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
RPbio reported separate results for FY2025: revenue of US$94.5M (+9.9% year on year), operating profit of US$3.61M (from a loss a year earlier) and net income of US$2.91M (from a loss a year earlier).
Earnings · Feb 13